A bladder cancer study identified mitochondrial translation release factor MTRF1 as a suppressor of cisplatin resistance, linking restoration of MTRF1 to ferroptosis vulnerability. Published in Cell Death Discovery, the work suggests that resistant cell models have lower MTRF1 levels, and that bringing MTRF1 back reduces IC50 values and suppresses multiple malignant phenotypes. Mechanistically, the researchers report changes in canonical ferroptosis markers—higher intracellular iron and lipid peroxidation signals, increased ACSL4, and reduced GPX4 and SLC7A11—alongside an interaction between MTRF1 and the mitochondrial transporter SLC25A5. They also describe a pathway where MTRF1 promotes ubiquitin-proteasome degradation of SLC25A5 via OTUB1 displacement. The preclinical data position MTRF1 as both a potential biomarker and a target to improve cisplatin durability in advanced bladder cancer settings.